左炔诺孕酮宫内装置非手术治疗医学上不适合手术的绝经后非典型子宫内膜增生和1级子宫内膜癌
回顾性图表综述纳入2002至2013年两家学术医疗系统内由妇科肿瘤医生放置左炔诺孕酮宫内装置的41例绝经后非典型子宫内膜增生/子宫内膜上皮内瘤变及1级子宫内膜样癌患者,36例(88%)随访可评估反应,完全缓解18/36(50%),无反应8例(22%),部分缓解3例(8%),疾病进展7例(19%),完全缓解者中4/18(22%) later复发。
要点
- 完全缓解率50%(18/36),无反应22%(8/36),部分缓解8%(3/36),进展19%(7/36)。
- 完全缓解者中22%(4/18)出现增生或癌复发。
- 治疗有效者治疗后活检孕激素受体表达显著较低。
核心结论
- 宫内左炔诺孕酮是绝经后非典型子宫内膜增生/子宫内膜上皮内瘤变及1级子宫内膜样癌且不适合标准手术者的可行治疗选择。
- 本系列缓解率与已发表的绝经前患者报告相似,并包括转为良性子宫内膜后复发的病例。
研究设计与样本
- 回顾性图表综述,纳入2002至2013年两家学术医疗系统内由妇科肿瘤医生放置左炔诺孕酮宫内装置的41例绝经后非典型子宫内膜增生/子宫内膜上皮内瘤变及1级子宫内膜样癌患者。
- 对可获取的组织块进行孕激素受体表达的免疫组化染色评估。
主要发现
- 41例患者接受左炔诺孕酮宫内装置治疗,36例(88%)随访足以评估反应。
- 36例中完全缓解18例(50%),无反应8例(22%),部分缓解3例(8%),疾病进展7例(19%)。
- 18例完全缓解者中4例(22%) later出现增生或癌复发。
- 研究期间4例(10%)死亡,均无转移性疾病证据,其中1例死于I期疾病子宫切除术后围手术期并发症。
- 治疗有效者治疗后活检孕激素受体表达显著较低。
关键数值与推荐
- 完全缓解:18/36(50%);无反应:8/36(22%);部分缓解:3/36(8%);疾病进展:7/36(19%)。
- 完全缓解后复发:4/18(22%)。
- 死亡:4/41(10%)。
临床怎么用
- 对于绝经后非典型子宫内膜增生/子宫内膜上皮内瘤变及1级子宫内膜样癌且不适合标准手术者,宫内左炔诺孕酮是可行治疗选择。
- 完全缓解后仍需注意增生或癌复发的可能。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the endometrial response rates to treatment with the levonorgestrel intrauterine device in post-menopausal women with atypical hyperplasia/endometrial intraepithelial neoplasia and grade 1 endometrioid (AH/EC) endometrial carcinoma who are not surgical candidates. METHODS: Chart review was undertaken of patients with AH/EC who underwent levonorgestrel intrauterine device insertion by a gynecologic oncologist within two academic health systems between 2002 and 2013. When available, tissue blocks were evaluated with immunohistochemical staining for progesterone receptor expression. RESULTS: A total of 41 patients received treatment for AH/EC with the levonorgestrel intrauterine device. Follow up sufficient to assess response occurred in 36 women (88%). Complete response was documented in 18 of 36 women (50%), no response in 8 patients (22%), partial response in 3 women (8%) and progression of disease in 7 patients (19%). Four of 18 patients with complete response (22%) later experienced relapse of hyperplasia or cancer. Four patients (10%) died during the study period: none had evidence of metastatic disease and 1 of the 4 woman died of perioperative complications following hysterectomy for stage I disease. Patients responding to treatment had significantly lower progesterone receptor expression on post-treatment biopsies. CONCLUSIONS: Intrauterine levonorgestrel is a viable treatment option for post-menopausal women with AH/EC who are poor candidates for standard surgical management. The response rate in this series is similar to published reports in premenopausal patients and includes cases of disease recurrence following conversion to benign endometrium.
引用
- Baker WD, Pierce SR, Mills AM, et al. Nonoperative management of atypical endometrial hyperplasia and grade 1 endometrial cancer with the levonorgestrel intrauterine device in medically ill post-menopausal women. Gynecol Oncol. 2017. PMID: 28427775. doi:10.1016/j.ygyno.2017.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。